ixekizumab
Taltz (ixekizumab) is an interleukin-17A inhibitor from Eli Lilly that neutralises a key cytokine driving inflammation in skin, joints, and spine. It treats moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in adults.
This page is based on EMA, FDA, and DailyMed prescribing information for ixekizumab; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
In psoriasis and related diseases, certain immune cells act like false alarms, constantly releasing a chemical called IL-17A. That chemical tells skin cells to multiply too fast, tells joint linings to swell, and keeps the whole area inflamed. Ixekizumab is an antibody that acts like a sponge for IL-17A: it soaks up the false alarm before it can reach the skin or joint, so the inflammation calms down and plaques thin, joints feel less stiff, and spinal pain eases.
In simple terms
Ixekizumab is an injection that blocks a protein called interleukin-17A (IL-17A). IL-17A is a messenger released by overactive immune cells that tells skin cells to grow too quickly, joint linings to swell, and spinal tissues to become inflamed. By neutralising IL-17A, ixekizumab lets skin plaques clear, reduces joint pain and swelling in psoriatic arthritis, and eases the inflammation that causes back pain in ankylosing spondylitis and non-radiographic axial spondyloarthritis.
In depth
Ixekizumab is a humanised IgG4 monoclonal antibody that binds with high affinity to interleukin-17A (IL-17A), including its homodimeric and heterodimeric (IL-17A/F) forms, preventing them from engaging the IL-17 receptor complex (IL-17RA/IL-17RC). IL-17A signalling through Act1 and TRAF6 activates NF-κB, MAPK, and C/EBPβ, driving transcription of chemokines (CXCL1, CXCL8), antimicrobial peptides (β-defensins, S100 proteins), and matrix metalloproteinases that sustain neutrophilic inflammation in skin plaques, synovium, and entheses. By neutralising IL-17A, ixekizumab reduces the PASI score in plaque psoriasis, improves ACR responses in psoriatic arthritis, and reduces BASDAI and ASDAS in axial spondyloarthritis.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How ixekizumab, an IgG4 antibody, neutralises IL-17A and IL-17A/F
- Ixekizumab is an injection that blocks a protein called interleukin-17A (IL-17A).
- Ixekizumab is a humanised IgG4 monoclonal antibody that binds with high affinity to interleukin-17A (IL-17A), including its homodimeric and heterodimeric (IL-17A/F) forms, preventing them from engaging the IL-17 receptor complex (IL-17RA/IL-17RC).
- IL-17A signalling through Act1 and TRAF6 activates NF-κB, MAPK, and C/EBPβ, driving transcription of chemokines (CXCL1, CXCL8), antimicrobial peptides (β-defensins, S100 proteins), and matrix metalloproteinases that sustain neutrophilic inflammation in skin plaques, synovium, and entheses.
- By neutralising IL-17A, ixekizumab reduces the PASI score in plaque psoriasis, improves ACR responses in psoriatic arthritis, and reduces BASDAI and ASDAS in axial spondyloarthritis.
Target: Interleukin-17A (IL-17A)
A pro-inflammatory cytokine produced mainly by Th17 cells, γδ T cells, and ILC3s; IL-17A stimulates keratinocytes, fibroblasts, and synovial cells to release chemokines, antimicrobial peptides, and matrix metalloproteinases that drive skin plaque formation, joint inflammation, and new bone remodelling.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in European Union
EMA- Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy
- Treatment of moderate to severe plaque psoriasis in children from 6 years of age with a body weight of at least 25 kg and adolescents who are candidates for systemic therapy
- Treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or are intolerant of, one or more DMARD therapies, alone or in combination with methotrexate
- Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy
- Treatment of adult patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have responded inadequately to NSAIDs
- Treatment of active juvenile psoriatic arthritis in patients 6 years of age and older weighing at least 25 kg who have had an inadequate response to conventional therapy
- Treatment of active enthesitis-related arthritis in patients 6 years of age and older weighing at least 25 kg who have had an inadequate response to conventional therapy
Approved uses in United States
FDA- Moderate-to-severe plaque psoriasis in patients aged 6 years or older who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis in adults
- Active ankylosing spondylitis in adults
- Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
Approved uses in United States
DailyMed- Moderate-to-severe plaque psoriasis in patients 6 years of age and older who are candidates for systemic therapy or phototherapy
- Active psoriatic arthritis in adults
- Active ankylosing spondylitis in adults
- Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults
Official sources
The statements on this page trace back to these records.
- Taltz (ixekizumab) — Summary of product characteristics and package leaflet, English version
European Medicines Agency
- U.S. Food and Drug Administration: TALTZ prescribing information
U.S. Food and Drug Administration
- DailyMed: TALTZ prescribing information
DailyMed, U.S. National Library of Medicine
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.